Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Myeloid-derived suppressor cells (MDSCs) are key immunosuppressive cells within the tumor microenvironment (TME).
• MDSCs inhibit anti-tumor immune responses mediated by T cells, NK cells, and dendritic cells.
• Their abnormal differentiation promotes immune escape, driving tumor progression and metastasis.

Purpose of the Study:

• To review the biological features of MDSCs in the TME.
• To explore MDSCs as potential targets for cancer immunotherapy.
• To discuss strategies for reprogramming the TME to overcome MDSC-mediated immunosuppression.

Main Methods:

• Literature review of MDSC biology and function in the TME.
• Analysis of current and emerging immunotherapeutic approaches targeting MDSCs.
• Summary of research on combinatorial strategies for enhanced cancer treatment.

Main Results:

• MDSCs exhibit potent immunosuppressive capabilities within the TME.
• Therapeutic strategies aim to prevent MDSC immunosuppression, promote differentiation, and reduce their abundance.
• Understanding MDSC generation and suppression mechanisms is crucial for developing effective treatments.

Conclusions:

• Targeting MDSCs is a promising avenue for cancer immunotherapy.
• Reprogramming the TME from immunosuppressive to immunostimulatory is essential.
• Further research into MDSC mechanisms will guide rational combinatorial strategies to improve patient outcomes.